Advertisement

Organ Failure and Acute Pancreatitis

  • Colin D. JohnsonEmail author
Chapter

Abstract

This chapter discusses the relationship of organ failure to outcome in acute pancreatitis. Current definition of severe acute pancreatitis includes the persistence of organ failure for more than 48 h, such patients have at least 35 % mortality. Organ failure that resolves is termed transient and defines moderately severe disease.

Most patients with organ failure show signs of the systemic inflammatory response syndrome (SIRS), and this may be an early marker of severe pancreatitis.

Treatment measures currently available are supportive, with provision of adequate (but not excessive) fluid resuscitation, oxygen supplements, and pain relief. The use of intravenous contrast for CT should be avoided if possible during the first week.

The evidence to support the choice of resuscitation fluid (Ringer lactate) and the use of early goal-directed therapy is described. Future advances will come from better understanding of the complex pathways that mediate SIRS and the development of agents able to block this response.

Keywords

Acute Pancreatitis Organ Failure Systemic Inflammatory Response Syndrome Severe Acute Pancreatitis Hydroxyethyl Starch 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bradley III EL. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993;128(5):586–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23(10):1638–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–10.PubMedCrossRefGoogle Scholar
  4. 4.
    Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–11.PubMedCrossRefGoogle Scholar
  5. 5.
    Petrov MS, Shanbhag S, Chakraborty M, Phillips AR, Windsor JA. Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. Gastroenterology. 2010;139(3):813–20.PubMedCrossRefGoogle Scholar
  6. 6.
    Rau BM, Bothe A, Kron M, Beger HG. Role of early multisystem organ failure as major risk factor for pancreatic infections and death in severe acute pancreatitis. Clin Gastroenterol Hepatol. 2006;4(8):1053–61.PubMedCrossRefGoogle Scholar
  7. 7.
    Glisic T, Sijacki A, Vuković V, Subotić A. [Bernard Organ Failure Score in estimation of most severe forms of acute pancreatitis]. Srp Arh Celok Lek. 2009;137(3–4):166–70.PubMedCrossRefGoogle Scholar
  8. 8.
    Dambrauskas Z, Gulbinas A, Pundzius J, Barauskas G. Value of the different prognostic systems and biological markers for predicting severity and progression of acute pancreatitis. Scand J Gastroenterol. 2010;45(7–8):959–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Mason JM, Babu BI, Bagul A, Siriwardena AK. The performance of organ dysfunction scores for the early prediction and management of severity in acute pancreatitis: an exploratory phase diagnostic study. Pancreas. 2010;39(7):1104–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Le Gall JR, Klar J, Lemeshow S, Saulnier F, Alberti C, Artigas A, et al. The logistic organ dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. JAMA. 1996;276(10):802–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Singh RK, Poddar B, Baronia AK, Azim A, Gurjar M, Singhal S, et al. Audit of patients with severe acute pancreatitis admitted to an intensive care unit. Indian J Gastroenterol. 2012;31(5):243–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Juneja D, Gopal PB, Ravula M. Scoring systems in acute pancreatitis: which one to use in intensive care units? J Crit Care. 2010;25(2):358.e9–15.CrossRefGoogle Scholar
  13. 13.
    Mole DJ, McClymont KL, Lau S, Mills R, Stamp-Vincent C, Garden OJ, et al. Discrepancy between the extent of pancreatic necrosis and multiple organ failure score in severe acute pancreatitis. World J Surg. 2009;33(11):2427–32.PubMedCrossRefGoogle Scholar
  14. 14.
    Ranson JH, Rifkind KM, Roses DF, Fink SD, Eng K, Localio SA, et al. Objective early identification of severe acute pancreatitis. Am J Gastroenterol. 1974;61(6):443–51.PubMedGoogle Scholar
  15. 15.
    Blamey SL, Imrie CW, O’Neill J, Gilmour WH, Carter DC. Prognostic factors in acute pancreatitis. Gut. 1984;25(12):1340–6.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Larvin M, McMahon MJ. APACHE-II score for assessment and monitoring of acute pancreatitis. Lancet. 1989;2(8656):201–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut. 2001;48(1):62–9.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Buter A, Imrie CW, Carter CR, Evans S, McKay CJ. Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. Br J Surg. 2002;89(3):298–302.PubMedCrossRefGoogle Scholar
  19. 19.
    Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut. 2004;53(9):1340–4.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Mofidi R, Duff MD, Wigmore SJ, Madhavan KK, Garden OJ, Parks RW. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. Br J Surg. 2006;93(6):738–44.PubMedCrossRefGoogle Scholar
  21. 21.
    Singh VK, Wu BU, Bollen TL, Repas K, Maurer R, Mortele KJ, et al. Early systemic inflammatory response syndrome is associated with severe acute pancreatitis. Clin Gastroenterol Hepatol. 2009;7(11):1247–51.PubMedCrossRefGoogle Scholar
  22. 22.
    Thandassery RB, Yadav TD, Dutta U, Appasani S, Singh K, Kochhar R. Dynamic nature of organ failure in severe acute pancreatitis: the impact of persistent and deteriorating organ failure. HPB (Oxford). 2013;15(7):523–8.CrossRefGoogle Scholar
  23. 23.
    Burch VC, Tarr G, Morroni C. Modified early warning score predicts the need for hospital admission and inhospital mortality. Emerg Med J. 2008;25(10):674–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Gardner-Thorpe J, Love N, Wrightson J, Walsh S, Keeling N. The value of Modified Early Warning Score (MEWS) in surgical in-patients: a prospective observational study. Ann R Coll Surg Engl. 2006;88(6):571–5.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Goldhill DR, McNarry AF, Mandersloot G, McGinley A. A physiologically-based early warning score for ward patients: the association between score and outcome. Anaesthesia. 2005;60(6):547–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Subbe CP, Davies RG, Williams E, Rutherford P, Gemmell L. Effect of introducing the Modified Early Warning score on clinical outcomes, cardio-pulmonary arrests and intensive care utilisation in acute medical admissions. Anaesthesia. 2003;58(8):797–802.PubMedCrossRefGoogle Scholar
  27. 27.
    Subbe CP, Kruger M, Rutherford P, Gemmel L. Validation of a modified Early Warning Score in medical admissions. QJM. 2001;94(10):521–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Garcea G, Gouda M, Hebbes C, Ong SL, Neal CP, Dennison AR, et al. Predictors of severity and survival in acute pancreatitis: validation of the efficacy of early warning scores. Pancreas. 2008;37(3):e54–61.PubMedCrossRefGoogle Scholar
  29. 29.
    Garcea G, Jackson B, Pattenden CJ, Ong SL, Neal CP, Dennison AR, et al. Progression of early warning scores (EWS) in patients with acute pancreatitis: a re-evaluation of a retrospective cohort of patients. Postgrad Med J. 2008;84(991):271–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Garcea G, Jackson B, Pattenden CJ, Sutton CD, Neal CP, Dennison AR, et al. Early warning scores predict outcome in acute pancreatitis. J Gastrointest Surg. 2006;10(7):1008–15.PubMedCrossRefGoogle Scholar
  31. 31.
    Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med. 1997;25(11):1789–95.PubMedCrossRefGoogle Scholar
  32. 32.
    Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13(4 Suppl 2):e1–15.Google Scholar
  33. 33.
    Baillargeon JD, Orav J, Ramagopal V, Tenner SM, Banks PA. Hemoconcentration as an early risk factor for necrotizing pancreatitis. Am J Gastroenterol. 1998;93(11):2130–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Remes-Troche JM, Duarte-Rojo A, Morales G, Robles-Díaz G. Hemoconcentration is a poor predictor of severity in acute pancreatitis. World J Gastroenterol. 2005;11(44):7018–23.PubMedGoogle Scholar
  35. 35.
    Lankisch PG, Mahlke R, Blum T, Bruns A, Bruns D, Maisonneuve P, et al. Hemoconcentration: an early marker of severe and/or necrotizing pancreatitis? A critical appraisal. Am J Gastroenterol. 2001;96(7):2081–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Gan SI, Romagnuolo J. Admission hematocrit: a simple, useful and early predictor of severe pancreatitis. Dig Dis Sci. 2004;49(11–12):1946–52.PubMedCrossRefGoogle Scholar
  37. 37.
    Brown A, Orav J, Banks PA. Hemoconcentration is an early marker for organ failure and necrotizing pancreatitis. Pancreas. 2000;20(4):367–72.PubMedCrossRefGoogle Scholar
  38. 38.
    Gardner TB, Olenec CA, Chertoff JD, Mackenzie TA, Robertson DJ. Hemoconcentration and pancreatic necrosis: further defining the relationship. Pancreas. 2006;33(2):169–73.PubMedCrossRefGoogle Scholar
  39. 39.
    Kuwabara K, Matsuda S, Fushimi K, Ishikawa KB, Horiguchi H, Fujimori K. Early crystalloid fluid volume management in acute pancreatitis: association with mortality and organ failure. Pancreatology. 2011;11(3):351–61.PubMedCrossRefGoogle Scholar
  40. 40.
    Du XJ, Hu WM, Xia Q, Huang ZW, Chen GY, Jin XD, et al. Hydroxyethyl starch resuscitation reduces the risk of intra-abdominal hypertension in severe acute pancreatitis. Pancreas. 2011;40(8):1220–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Mao EQ, Tang YQ, Fei J, Qin S, Wu J, Li L, et al. Fluid therapy for severe acute pancreatitis in acute response stage. Chin Med J (Engl). 2009;122(2):169–73.Google Scholar
  42. 42.
    Wu BU, Hwang JQ, Gardner TH, Repas K, Delee R, Yu S, et al. Lactated Ringer’s solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2011;9(8):710–7.e1.PubMedCrossRefGoogle Scholar
  43. 43.
    Wang MD, Ji Y, Xu J, Jiang DH, Luo L, Huang SW. Early goal-directed fluid therapy with fresh frozen plasma reduces severe acute pancreatitis mortality in the intensive care unit. Chin Med J (Engl). 2013;126(10):1987–8.Google Scholar
  44. 44.
    Hartman H, Sippola T, Kupcinskas J, Lindström O, Johnson C, Regnér S. Raised intestinal fatty acid binding protein correlates to severe acute pancreatitis. Abstract presented at the 45th Annual Meeting of the European Pancreatic Club, June 26–29, 2013, Zurich, Switzerland. Pancreatology. 2013;13(3):S68.CrossRefGoogle Scholar
  45. 45.
    Juvonen PO, Alhava EM, Takala JA. Gastric tonometry in assessing splanchnic tissue perfusion in acute pancreatitis. Scand J Gastroenterol. 2000;35(3):318–21.PubMedCrossRefGoogle Scholar
  46. 46.
    Kovacs GC, Telek G, Hamar J, Furesz J, Regoly-Merei J. Prolonged intestinal mucosal acidosis is associated with multiple organ failure in human acute pancreatitis: gastric tonometry revisited. World J Gastroenterol. 2006;12(30):4892–6.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Helm JF, Venu RP, Geenen JE, Hogan WJ, Dodds WJ, Toouli J, et al. Effects of morphine on the human sphincter of Oddi. Gut. 1988;29(10):1402–7.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Thune A, Baker RA, Saccone GT, Owen H, Toouli J. Differing effects of pethidine and morphine on human sphincter of Oddi motility. Br J Surg. 1990;77(9):992–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Peiro AM, Martínez J, Martínez E, de Madaria E, Llorens P, Horga JF, et al. Efficacy and tolerance of metamizole versus morphine for acute pancreatitis pain. Pancreatology. 2008;8(1):25–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Fleszler F, Friedenberg F, Krevsky B, Friedel D, Braitman LE. Abdominal computed tomography prolongs length of stay and is frequently unnecessary in the evaluation of acute pancreatitis. Am J Med Sci. 2003;325(5):251–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Formela LJ, Galloway SW, Kingsnorth AN. Inflammatory mediators in acute pancreatitis. Br J Surg. 1995;82(1):6–13.PubMedCrossRefGoogle Scholar
  52. 52.
    Pezzilli R. Pharmacotherapy for acute pancreatitis. Expert Opin Pharmacother. 2009;10(18):2999–3014.PubMedCrossRefGoogle Scholar
  53. 53.
    Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev. 2000;52(1):91–112.PubMedGoogle Scholar
  54. 54.
    Lium B, Ruud TE, Pillgram-Larsen J, Stadaas JO, Aasen AO. Sodium taurocholate-induced acute pancreatitis in pigs. Pathomorphological studies of the pancreas in untreated animals and animals pretreated with high doses of corticosteroids or protease inhibitors. Acta Pathol Microbiol Immunol Scand A. 1987;95(6):377–82.PubMedGoogle Scholar
  55. 55.
    Ruud TE, Aasen AO, Pillgram-Larsen J, Stadaas J, Aune S. Effects of protease inhibitor pretreatment on hemodynamic performances and survival rate in experimental, acute pancreatitis. Adv Exp Med Biol. 1986;198(Pt B):413–21.PubMedCrossRefGoogle Scholar
  56. 56.
    Ruud TE, Aasen AO, Pillgram-Larsen J, Stadaas JO. Effects on peritoneal proteolysis and hemodynamics of prophylactic infusion with C1 inhibitor in experimental acute pancreatitis. Scand J Gastroenterol. 1986;21(8):1018–24.PubMedCrossRefGoogle Scholar
  57. 57.
    Czaller I, Molnár K, Csuka D, Varga L, Farkas H. Successful outcome using C1-inhibitor concentrate in acute pancreatitis caused by hereditary angioedema. Gastroenterol Nurs. 2011;34(1):60–3.PubMedCrossRefGoogle Scholar
  58. 58.
    Cancian M, Bendo R, Maggioni L, Ossi E, Vettore G, Realdi G. Hereditary angioedema-induced acute pancreatitis: clinical picture and effects of C1-esterase inhibitor replacement. Mol Immunol. 2008;45(16):4157–8.CrossRefGoogle Scholar
  59. 59.
    Schneider DT, Nürnberger W, Stannigel H, Bönig H, Göbel U. Adjuvant treatment of severe acute pancreatitis with C1 esterase inhibitor concentrate after haematopoietic stem cell transplantation. Gut. 1999; 45(5):733–6.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Testoni PA, Cicardi M, Bergamaschini L, Guzzoni S, Cugno M, Buizza M, et al. Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc. 1995;42(4):301–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of SurgeryUniversity Hospital SouthamptonSouthamptonUK

Personalised recommendations